Randomized, open-label phase 2 study comparing frontline dovitinib versus sorafenib in patients with advanced hepatocellular carcinoma

بواسطة Ann Lii Cheng, Sumitra Thongprasert, Ho Yeong Lim, Wattana Sukeepaisarnjaroen, Tsai Shen Yang, Cheng Chung Wu, Yee Chao, Stephen L. Chan, Masatoshi Kudo, Masafumi Ikeda, Yoon Koo Kang, Hongming Pan, Kazushi Numata, Guohong Han, Binaifer Balsara, Yong Zhang, Ana Marie Rodriguez, Yi Zhang, Yongyu Wang, Ronnie T.P. Poon
منشور في 2018